About Rejoni
Rejoni is a company based in Bedford (United States) founded in 2020. Rejoni has raised $41.25 million across 2 funding rounds from investors including Sparta Group, Sparta Capital and CHV. Rejoni offers products and services including Juveena Hydrogel. Rejoni operates in a competitive market with competitors including Sprout Pharmaceuticals, ObsEva, Hope Medicine, Gameto and ClearFlow, among others.
- Headquarter Bedford, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$41.25 M (USD)
in 2 rounds
-
Latest Funding Round
$26.25 M (USD), Series B
Feb 10, 2023
-
Investors
Sparta Group
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rejoni
Rejoni offers a comprehensive portfolio of products and services, including Juveena Hydrogel.
Gel to prevent intrauterine adhesions after uterine surgery procedures.
People of Rejoni
Unlock access to complete
Unlock access to complete
Funding Insights of Rejoni
Rejoni has successfully raised a total of $41.25M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $26.25 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $26.2M
-
First Round
First Round
(10 Sep 2020)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2023 | Amount | Series B - Rejoni | Valuation | CHV | |
| Sep, 2020 | Amount | Series B - Rejoni | Valuation | Ascension Ventures |
Investors in Rejoni
Rejoni has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Sparta Group, Sparta Capital and CHV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Strategic investments in healthcare technologies and data innovations.
|
Founded Year | Domain | Location | |
|
Delos Capital is engaged in private equity and financial advisory services.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rejoni
Financial Statements - Rejoni
Rejoni Comparisons
Competitors of Rejoni
Rejoni operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sprout Pharmaceuticals, ObsEva, Hope Medicine, Gameto and ClearFlow, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for hypoactive sexual desire disorder in women are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for women's reproductive health and pregnancy are developed.
|
|
| domain | founded_year | HQ Location |
Monoclonal antibodies are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for fertility and menopause treatments are developed.
|
|
| domain | founded_year | HQ Location |
Anti-clogging technologies for medical drainage catheters are developed.
|
Latest news on Rejoni
Frequently Asked Questions about Rejoni
Rejoni was founded in 2020.
Rejoni is headquartered in Bedford, United States.
Rejoni is a funded company, having raised a total of $41.25M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Sep 10, 2020.
Rejoni was founded in 2020 and is based in Bedford, United States. Focus is placed on the biotechnology sector, where therapeutics for womens health conditions are developed. Operations center on creating a soft gel-like material named Juveena Hydrogel, which is designed to prevent intrauterine adhesions after uterine surgery. This approach addresses post-surgical complications in gynecological care through targeted medical interventions.
Rejoni's top competitors include Sprout Pharmaceuticals, Hope Medicine and Gameto.
Rejoni offers Juveena Hydrogel.
Rejoni has 8 investors. Key investors include Sparta Group, Sparta Capital, CHV, Ascension Ventures, and Delos Capital.